KLRC1 and Miyoshi myopathy: The CRISPR-Cas9 gene-editing approach developed by research teams can achieve approximately 80% knockout efficiency of the KLRC1 gene in primary NK cells, and studies have demonstrated that deletion of the KLRC1 gene significantly enhances NK cell cytotoxicity against MM cells [48].